Additional file 1: of Feasibility of serum CGRP measurement as a biomarker of chronic migraine: a critical reappraisal

Table S1. Univariate analysis for serum CGRP concentration. (DOC 35 kb

Additional file 2: of l-asparaginase-based regimens followed by allogeneic hematopoietic stem cell transplantation improve outcomes in aggressive natural killer cell leukemia

Summary of patients who underwent HSCT after SMILE or VIDL chemotherapy. One patient underwent autologous HSCT and 7 patients received allogeneic HSCT. No engraftment failure or treatment-related mortality occurred. But, 2 patients died from disease relapse (Autologous; 1, Allogeneic; 1). (DOCX 17 kb

Additional file 3: of l-asparaginase-based regimens followed by allogeneic hematopoietic stem cell transplantation improve outcomes in aggressive natural killer cell leukemia

Survival according to EBV DNA titer and treatment response (A) Survival according to baseline EBV DNA. (A) Baseline EBV negativity did not affect OS (p = 0.307). (B) Negativity EBV DNA after treatment was significantly associated with OS (p = 0.004). (C) Change pattern (decreasing vs. increasing) of EBV DNA titer during treatment was not significantly associated with OS (p = 0.069). (D) Clinical treatment response showed significant association with OS (p < 0.001). (DOC 103 kb

Results of QuantiFERON-TB Gold In-Tube and T-SPOT.TB tests in initial evaluation of LTBI in patients with rheumatic diseases scheduled for TNF-α antagonist therapy.

<p>LTBI, latent tuberculosis infection; TNF, tumor necrosis factor; QFT-GIT, QuantiFERON-TB Gold In-Tube.</p><p>^aAll QFT-GIT indeterminate results occurred due to failure to generate an IFN-γ response to mitogens, and all T-SPOT.TB indeterminate results were due to excessive response of negative controls.</p><p>^bOne QFT-GIT-indeterminate patient with a 10 mm tuberculin skin test result received TB medication.</p><p>Results of QuantiFERON-TB Gold In-Tube and T-SPOT.TB tests in initial evaluation of LTBI in patients with rheumatic diseases scheduled for TNF-α antagonist therapy.</p

Results of two IGRAs stratified by baseline interferon-γ responses in different groups.

<p>IGRA, interferon gamma release assay; QFT-GIT, QuantiFERON-TB Gold In-Tube; +, positive; -, negative; I, indeterminate.</p><p>Results of two IGRAs stratified by baseline interferon-γ responses in different groups.</p

Characteristics of patients with active TB diseases during the follow-up period (218–675 days).

<p>TB, tuberculosis; BCG, Bacillus Calmette Guérin; TST, tuberculin skin test; IGRA, interferon-gamma release assays; QFT-GIT, QuantiFERON-TB Gold In-Tube; TNF, tumor necrosis factor; CD, Crohn’s disease; RA, rheumatoid arthritis; AS, ankylosing spondylitis; COPD, chronic obstructive pulmonary disease; N, negative; P, positive; NT, not tested; I, infliximab; E, etanercept; A, adalimumab; BAL, bronchoalveolar lavage; AFB, acid-fast bacilli.</p><p>^aRetrospective review of initial chest radiography revealed several tiny fibrotic nodules in the right upper lobe. This finding was not recognized as an indication for LTBI treatment by the attending physician at the time of patient enrollment.</p><p>Characteristics of patients with active TB diseases during the follow-up period (218–675 days).</p

Comparison of patient characteristics according to baseline IGRA results.

<p>The data are presented as median and interquartile range or as number (%).</p><p>IGRA, interferon gamma release assay; QFT-GIT, QuantiFERON-TB Gold In-Tube; +, positive; -, negative; I, indeterminate.</p><p>^a<i>P</i> value was less than 0.05.</p><p>^bUlcerative colitis, Crohn’s disease, spondyloarthropathy and psoriatic arthropathy were included.</p><p>^cForty patients were tested for tuberculin skin test.</p><p>Comparison of patient characteristics according to baseline IGRA results.</p

Characteristics of patients with discordant results on the TST and QFT assays.

<p>Characteristics of patients with discordant results on the TST and QFT assays.</p

Patient characteristics.

<p>The data are presented as median and interquartile range or as number (%).</p><p>TB, tuberculosis; +, positive; TNF, tumor necrosis factor.</p><p>^aInflammatory bowel disease (n = 5; 2 with ulcerative colitis and 3 with Crohn’s disease), spondyloarthropathy (n = 2), and psoriatic arthropathy (n = 3)</p><p>^bOf 156 patients included in this study, 150 were tested by tuberculin skin test.</p><p>^cA total of 137 patients received TNF-α antagonist therapy. Twenty-seven patients were administered two or more drugs.</p><p>Patient characteristics.</p

Characteristics of five patients who developed active tuberculosis after initiation of anti-TNF therapy.

<p>Characteristics of five patients who developed active tuberculosis after initiation of anti-TNF therapy.</p